SAN DIEGO, CA, May 15, 2014 /PRNewswire/ – CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1 billion. Of these notes, $300 million will mature in 2017 and will bear interest at an annual rate of 1.450 percent; $400 million will mature in 2024 and will bear interest at an annual rate of 3.875 percent and $300 million will mature in 2044 and will bear interest at an annual rate of 4.875 percent.
CareFusion intends to use a portion of the net proceeds from the offering to repay at maturity its $450 million in aggregate outstanding principal amount of 5.125 percent senior notes due 2014. The company intends to use the remaining net proceeds of the offering for general corporate purposes. The offering is expected to close on May 22, 2014, subject to customary closing conditions.
Barclays Capital Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint book-running managers and representatives of the several underwriters. A copy of the preliminary prospectus supplement and the accompanying base prospectus, which is filed as part of CareFusion's effective shelf registration statement on Form S-3 (File No. 333-195887), may be obtained from any of the joint book-running managers by calling Barclays Capital Inc. at 888-603-5847, J.P. Morgan Securities LLC at 212-834-4533, and Merrill Lynch, Pierce, Fenner & Smith Incorporated at 1-800-294-1322. An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission's website at www.sec.gov. The notes are being offered pursuant to an effective registration statement on Form S-3 (File No. 333-195887) that CareFusion previously filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the notes described herein, nor shall there be any sale of these notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction. The offering of the notes will be made only by means of a prospectus supplement and the accompanying base prospectus.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.